*Cheng-Hock Toh,1,2 Yasir Alhamdi1
1. Institute of Infection and Global Health, University of Liverpool, Liverpool, UK
2. Roald Dahl Haemostasis and Thrombosis Centre, Royal Liverpool University Hospital, Liverpool, UK
*Correspondence to Toh@liverpool.ac.uk
Disclosure: The authors have declared no conflicts of interest.
Received: 24.05.16 Accepted: 19.08.16
Citation: EMJ. 2016;1:98-105.
The use of fresh frozen plasma, cryoprecipitate, and platelets has been the mainstay of approaches to correct coagulopathies that can arise in the perioperative setting. Limitations include the time delay from obtaining results of coagulation screens to the availability of thawed fresh frozen plasma and the potential of fluid overload. With advances in both global haemostatic testing and concentrates of coagulation factors, there are increasing opportunities for innovative practice. However, there remains a paucity of studies that can provide good quality, unbiased evidence. These issues are elaborated here to form the basis for future study.